Prescription Drugs Market Poised for Explosive Growth: Key Trends, Innovations, and Opportunities Driving $2.2B Industry by 2032 | Major players - F. Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd

Market Size and Growth:

The Global Prescription Drugs Market Size reached US$ 1.23 billion in 2024 and is expected to reach US$ 2.20 billion by 2032, growing with a CAGR of 8.9% during the forecast period 2025-2032. The Market is growing due to rising chronic disease prevalence and continuous advancements in drug development supported by strong healthcare spending worldwide.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/prescription-drugs-market?sz

The Prescription Drugs Market comprises medications that require authorization from licensed healthcare professionals to treat, manage, or prevent medical conditions. It includes branded and generic pharmaceuticals developed through rigorous clinical research and regulated for safety and efficacy. This market spans therapeutic categories such as chronic diseases, infectious disorders, and specialty treatments, driven by innovation, regulatory oversight, and rising healthcare demand.

United States: Recent Developments of Prescription Drugs Market

✅ In September 2025, Pfizer reached a landmark agreement with the U.S. government to lower prescription drug costs for patients through a direct-to-consumer platform offering discounts up to 85% off list prices.

✅ In October 2025, the FDA launched a pilot program for faster review of abbreviated new drug applications to accelerate approvals and encourage U.S.-based manufacturing investments.

✅ In November 2025, Medicare announced negotiated prices for 15 high-priced drugs, projecting a 36% reduction in spending starting in 2027.

Japan: Recent Developments of Prescription Drugs Market

✅ In September 2025, the FDA-related public meeting on Prescription Drug User Fee Act updates indirectly influenced global pharma strategies, but Japan focused on ongoing NHI pricing adjustments for prescription medicines amid aging population demands.

✅ In October 2025, regulatory efforts advanced to reduce drug lag with streamlined approvals for innovative therapies, projecting 43 new drugs entering the market.

✅ In November 2025, IQVIA projected Japan's NHI-listed prescription drug market to reach 11.9 trillion yen by FY2030, growing at a 1.2% CAGR from FY2025 due to steady demand.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/prescription-drugs-market?sz

Major FDA Approvals in 2025:

✅ Voyxact (sibeprenlimab-szsi) - Otsuka; accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN). Approval date: Nov 25, 2025.

✅ Itvisma (onasemnogene abeparvovec-brve) - Novartis; gene therapy approval expanded for a broader spinal muscular atrophy population. Approval date: Nov 24, 2025.

✅ Hyrnuo (sevabertinib) - Bayer; accelerated approval for HER2-mutant non-squamous non-small cell lung cancer. Approval date: Nov 19, 2025.

✅ Redemplo (plozasiran) - (triglyceride lowering for familial chylomicronemia syndrome). Approval date: Nov 18, 2025.

✅ Komzifti (ziftomenib) - (relapsed/refractory AML with NPM1 mutation). Approval date: Nov 13, 2025.

✅ (FDA's official Novel Drug Approvals 2025 page lists all novel approvals in Nov; see the agency list for full details and exact indication language).

Major Mergers & Acquisitions in 2025:

✅ Merck announced acquisition of Cidara Therapeutics (deal announced Nov 14, 2025).

✅ AbbVie completed acquisition of Gilgamesh Pharmaceuticals (closed Oct 17, 2025) - adds Bretisilocin to psychiatry pipeline.

✅ Alkermes → Avadel: Alkermes announced agreement/offer to acquire Avadel (transaction announced Oct 22; increased offer/amendments in mid-Nov).

✅ MSD (Merck outside US) / Verona Pharma - acquisition announced/closing activity in this period expanding respiratory portfolio (ensifentrine/Ohtuvayre).

✅ Abbott to acquire Exact Sciences (diagnostics; announced Nov 20, 2025 - sizeable deal ~US$21B; important to watch for diagnostic + companion-diagnostic synergies). (Note: diagnostics deal - included because it affects oncology diagnostic/therapeutic ecosystems.)

✅ Multiple smaller / strategic bolt-on deals: Evoke Pharma → QOL Medical (definitive agreement Nov 4, 2025); Chugai → Renalys (Oct 24, 2025); Cipla acquired Inzpera Healthsciences (India, early Nov).

Other Regulator Actions (EMA, India CDSCO) in Oct-Nov 2025:

✅ EMA CHMP (Nov 10-13, 2025) - CHMP recommended ~10 medicines for approval at its November meeting (various indications). (Recommendation step - national MA decisions follow).

✅ India - CDSCO / DCGI approvals & lists (Oct-Nov 2025) - CDSCO published October/late-Oct lists of new drug approvals; individual approvals reported (e.g., Pembrolizumab listing entry dated 19-Nov-2025, Daratumumab entry 30-Oct-2025 on CDSCO pages).

Major Players:

Key companies in the Prescription Drugs market include:

F. Hoffmann-La Roche Ltd
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GlaxoSmithKline plc
Novartis AG
Merck & Co., Inc.
Allergan
Dr. 'Reddy's Laboratories Ltd.

Segments Covered in the Prescription Drugs Market:

By Type: Branded, Generic.

By Therapy Area: Oncology, Immunology, Ophthalmology, Respiratory, Gastroenterology, Gynecology, Others.

By Route of Administration: Oral, Topical, Parenteral, Others.

Regional Analysis for Prescription Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=prescription-drugs-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Prescription Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Prescription Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Prescription Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Prescription Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Prescription Drugs market?

➠ Who are the global key manufacturers of the Prescription Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Prescription Drugs market opportunities and threats faced by the vendors in the global Prescription Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Prescription Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.